New insights into transcription factors and chromatin remodeling
longevity.technology
longevity.technology
Unfortunately, AP-1 is also involved in cancer.
From https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361657/
> Activator protein-1 (AP-1) is a transcription factor that consists of a diverse group of members including Jun, Fos, Maf, and ATF. AP-1 involves a number of processes such as proliferation, migration, and invasion in cells. Dysfunctional AP-1 activity is associated with cancer initiation, development, invasion, migration and drug resistance.
Mentioning AP-1 without mentioning its role in cancer is misleading. Many of the mechanisms that are involved with aging, likely have a role with controlling cancer by keeping cells, especially cells with damage, from proliferating or invading nearby or distant tissue.
Digestive tract cancers in particular are often confused by patients with other, benign issues and are therefore diagnosed too late.
https://www.cancer.gov/about-cancer/treatment/types/biomarke...
Is this really true? I know we are getting better in diagnosing cancers, so the time from initial diagnosis to death is longer, but it's not clear that overall lifespan of people with all cancers is any longer. If anything, because treatment starts sooner, quality of life may have diminshed.
It is definitely true that treatments for some cancers have improved over the last couple of decades. I find the immunotherapies particularly exciting and seemingly promising.
But in the broader cases I am not sure I could agree with your statement.
That’s good news, but that’s not what they asked.
A mole removal with local anesthetic by your local dermatologist will almost always lead to better outcomes than two rounds of surgery, chemo, and radiation to treat stage 4 metastatic melanoma.
It is still an artform though and procedures that lead to a long healthy life in a majority of patients still cause deaths in some others.
Hope you are doing well, and wishing you the very best.
We have gotten a lot better at treating cancer, in general, literally because we've gotten a lot better at treating specific types of cancer. There are no "broader cases", only cases of specific cancers which we've either gotten really good at treating, or which we haven't gotten really good at treating yet.
We are detecting cancers earlier than before. Which can mean that, without any change in treatment efficacy, people are "surviving longer" with the disease. Another biggie is that people are smoking significantly less than 20+ years ago (both smokers and secondary exposure). While we are continually finding new ways to slowly poison ourselves (eg PFAS), we have also reduced exposure to other environmental toxins: lead paint/gas, DDT, etc,
Cancer survival rate has gone up because of treatment accessibility and testing, not because of any major breakthroughs.
Animals that don't really age like the lobster, giant tortoise, bowhead whale, elephant, etc - also get cancer much less than we do.
iirc senescence blocks damaged (potentially pre-cancerous) cells from reproducing, but unlike p53 doesn't kill them. replacing sensescent cells means more cell divisions, which also risks a cancerous mutation. so reducing senescence probably means making p53 more sensitive and redundant.
I personally think this view is too simplistic about how our bodies work and overly optimistic that we a) won't hit other limiting factors that aren't hit today by ~100 and b) that interventions to stop senescence won't have unexpected side effects.
Medicine in its current form is just not prepared to deal with these things. It evolved to deal very well with infections and injuries, in both cases helping the body to heal itself, which it wants to do anyway.
Aging is different. An aging body actually wants to destroy itself. It intentionally disables self-repair mechanisms, allowing the diseases of old age to take over. It's the first time we have to override these internal goals. Treating these diseases individually, like we do now because it's the best we have to offer, is a losing game.
I guess these are hard questions for everyone and I don't want individuals reduced to a number in a dataset but mankind has certainly gotten itself in a bit of a pickle.
jfc the media telephone chain here is absurd. "Revealing a master controller of development and ageing" becomes "AP-1: The Master Regulator." A -> the is a pretty big jump. (https://www.uq.edu.au/news/article/2024/06/revealing-master-...)
Also - ugh these content mills are so lame. The university PR departments aren't helping - why a university feels it needs to contribute to lowering public trust in science by claiming every paper is a generation defining breakthrough is beyond me. But maybe pause for a second before breathlessly passing along a headline like 'master controller of aging and development uncovered'? And the underlying research (https://www.sciencedirect.com/science/article/pii/S155041312...) and techniques used etc is pretty interesting - please don't cut research funding to genetics a few years down the line when immortality fails to materialize like longevity.whatever promised.
From the paper:
• Multi-omic analysis of maturation and aging across >45 mouse and human cell types
• Common transcription factor pattern for chromatin remodeling in maturation and aging
• Encoded via relative abundance of AP-1, CTCF, and cell identity factor binding sites
• Remodeling mechanism activated by AP-1, stress, systemic factor, or PRC2 inhibition
C'mon the Science!
Put otherwise, Biden wouldn't be old at 81 if we completely understood the molecular biology of ageing. Unfortunately, we don't.
1. Our genes change as we age with some becoming more active, while others become less active.
2. The researchers found a special protein called AP-1 that acts like a master switch. As we get older, AP-1 becomes more active.
3. AP-1 turns on "adult" genes and turns down "young" genes. This happens in many different types of cells in our body.
4. These changes in gene activity are linked to the aging process and may explain why we experience age-related health issues.
5. Understanding this process could help scientists develop new ways to prevent or treat diseases that commonly affect older people, like Alzheimer's or diabetes.
From snippet in background for https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678392/:
"The Activator protein-1 (AP-1), is a group of transcription factors consisted of four sub-families: the Jun (c-Jun, JunB, JunD), Fos (c-Fos, FosB, Fra1, Fra2), Maf (musculoaponeurotic fibrosarcoma) (c-Maf, MafB, MafA. Mafg/f/k, Nrl), and the ATF-activating transcription factor (ATF2, LRF1/ATF3, BATF, JDP1, JDP2) protein families [21], characterized by pleiotropic effects and a central role in different aspects of the immune system such as T-cell activation, Th differentiation, T-cell anergy and exhaustion [22,23]. "
They found a correlation between AP-1 binding sites/motifs and genes with age related changes in expression through their analysis (https://www.sciencedirect.com/science/article/pii/S155041312...):
"This revealed that age-opening DARs had the highest enrichment for a subset of bZIP motifs, including AP-1 subunits FRA2, FRA, JUN, JUNB, FOS, ATF3, and BATF, compared with the other peak categories (Figures 4C and S5B). Conversely, age-closing DARs had the lowest AP-1 enrichment (Figures 4C and S5B). As broadly expressed pioneer factors,39,40 AP-1 family members are responsive to a variety of stimuli41 and have been linked to potentiating age-related pathologies and phenotypes.12,13,42,43,44,45 This makes them strong candidates for driving age-related chromatin opening. Highly stable cCREs showed intermediate enrichment levels for these AP-1 motifs (Figures 4C and S5B). However, a distinct feature of highly stable cCREs was very high CTCF motif enrichment levels and binding relative to all other peak categories (Figures 4D, S5B, and S5C)."